Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Aug 25, 2022 11:35am
177 Views
Post# 34919922

RE:RE:RE:Three payment streams

RE:RE:RE:Three payment streamsJimmy, look at the share price. It is in the shitt€r. 

The market doesn't think the upfront is very significant. Its as simple as that. 

I don't know anything more than what is said in the news releases but what I do think is that after going through the R&F debacle, he wouldn't dare mislead investors. The nature of the deal seems to be kept air tight and nobody has any clue, so in my opinion the market is pricing shares purely on historical mistrust of the CEO and a whole lot of doubt.

He said the deal would 1) turn Sirona into a profitable company; and 2) that the upfront AND milestones is significant. 

I can only assume that this deal with Abbvie is a good deal in totality. That in itself will fund the future pipelines. 
<< Previous
Bullboard Posts
Next >>